What is the recommended isoniazid dosage for a 6‑month (6H) treatment regimen in adults and children?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Isoniazid Dosing for 6-Month (6H) Treatment Regimen

For latent tuberculosis infection (LTBI), the 6-month isoniazid monotherapy regimen is an alternative option: adults receive 5 mg/kg (typically 300 mg) daily, and children receive 10-15 mg/kg (maximum 300 mg) daily. 1

Dosing by Population

Adults

  • Daily dosing: 5 mg/kg, typically 300 mg once daily 2
  • Twice-weekly dosing: 15 mg/kg, typically 900 mg (not recommended for 6-month regimen) 2
  • Maximum daily dose: 300 mg 3

Children

  • Daily dosing: 10-15 mg/kg once daily, maximum 300 mg 2, 3
  • Twice-weekly dosing: 20-30 mg/kg (not recommended for 6-month regimen) 2
  • Doses should be rounded up to facilitate administration 4

Clinical Context and Recommendations

The 6-month isoniazid regimen (6H) is classified as an alternative regimen rather than preferred for LTBI treatment 1. It is:

  • Strongly recommended for HIV-negative adults and children (moderate certainty evidence) 1
  • Conditionally recommended for HIV-positive adults and children (moderate certainty evidence) 1

Preferred regimens have replaced 6H in most scenarios due to better completion rates and shorter duration, including 3 months of weekly isoniazid-rifapentine (3HP) or 4 months of daily rifampin 1. The 6H regimen has lower treatment completion rates and higher hepatotoxicity risk compared to rifamycin-based regimens, which decreases its overall effectiveness despite good efficacy 1.

Administration Guidelines

  • Timing: Take 30-60 minutes before food or 2 hours after food 4
  • Frequency: Daily administration is standard; 5-7 days per week is acceptable 2
  • Duration: Complete 6 months (approximately 180 doses) 1

Pyridoxine (Vitamin B6) Supplementation

Pyridoxine 25-50 mg daily must be co-administered to all patients at risk of peripheral neuropathy 2, 4:

  • Pregnant women and breastfeeding infants
  • HIV-positive persons
  • Patients with diabetes, alcoholism, malnutrition, or chronic renal failure
  • Advanced age
  • Children receiving the increased 10-15 mg/kg dosing 5

For patients who develop peripheral neuropathy, increase pyridoxine to 100 mg daily 2.

Important Caveats

The 6H regimen should only be used after active tuberculosis disease is definitively excluded through appropriate clinical, radiographic, and bacteriologic evaluation 3. Using isoniazid monotherapy when active TB is present risks developing drug resistance.

Weight-based dosing is critical in children: The WHO revised pediatric isoniazid dosing upward from 5 mg/kg to 10-15 mg/kg in 2010 to achieve adequate drug exposures 6, 5. Lower doses (5 mg/kg) previously used are no longer recommended despite older studies showing efficacy 7.

For low body weight adults (particularly relevant in Asian populations), consider the 5 mg/kg weight-based calculation rather than the fixed 300 mg dose to avoid excessive exposure and adverse effects 4, 8.

Monitoring Requirements

  • Baseline liver function tests in all patients 4
  • Monthly monitoring if underlying liver disease, alcohol abuse, or hepatitis B coinfection 4
  • Clinical assessment for symptoms of hepatotoxicity (nausea, vomiting, abdominal pain, jaundice) 2
  • Adherence monitoring can be performed using INH test strips that detect isoniazid metabolites in urine 4

The evidence strongly supports that while 6H is effective for LTBI, shorter rifamycin-based regimens should be prioritized when feasible due to superior completion rates and comparable or better safety profiles 1.

Related Questions

What is the appropriate dosing regimen of Fixcom (rifampicin 120 mg, isoniazid 50 mg, pyrazinamide 300 mg, ethambutol 75 mg) for an adult weighing 45–54 kg, and how should it be administered and monitored?
What is the appropriate HRZE (isoniazid, rifampin, pyrazinamide, ethambutol) dosing regimen for a patient with a creatinine clearance of 63 mL/min?
Is vitamin B complex supplementation necessary for a patient receiving isoniazid and rifampicin?
What is the maximum dosage of Isoniazid (INH) for anti-tubercular treatment?
Can a woman with intestinal tuberculosis and a history of pulmonary tuberculosis be treated using an anti‑TB regimen that omits pyrazinamide?
What follow-up care or monitoring is needed three weeks after stopping levofloxacin (Levaquin)?
Is ofloxacin appropriate for contact lens wearers with bacterial conjunctivitis?
Which standard transthoracic (TTE) and transesophageal (TEE) echocardiographic views are used to measure the tricuspid valve annulus (≥40 mm on TTE) and intercommissural distance (≥70 mm on TEE), and how can the commissures, leaflets, and subvalvular apparatus be visualized?
Why does sitting on a fresh fistulotomy scar cause tension and spasm of the right coccygeal (coccygeus) muscle, and is this condition permanent?
How should I document a 1‑inch linear gingival laceration located superior to the maxillary central incisors, with a midline mandibular gingival split forming thin flaps that hang over the mandibular incisors?
How does aspirin interact with methotrexate, and what precautions should be taken?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.